IAXO-102 is a glycolipid and an antagonist of toll-like receptor 4 (TLR4). It inhibits lipid A-induced TLR4 activation in a cell-based assay (IC50 = 5.013 µM). IAXO-102 (10 mg/kg) reduces LPS-induced lethality in mice. It decreases angiotensin II-induced aortic expansion and rupture, as well as the incidence of abdominal aortic aneurysms, in ApoE-/- mice when administered at a dose of 3 mg/kg.
IAXO-102 is a glycolipid and an antagonist of toll-like receptor 4 (TLR4). It inhibits lipid A-induced TLR4 activation in a cell-based assay (IC50 = 5.013 µM). IAXO-102 (10 mg/kg) reduces LPS-induced lethality in mice. It decreases angiotensin II-induced aortic expansion and rupture, as well as the incidence of abdominal aortic aneurysms, in ApoE-/- mice when administered at a dose of 3 mg/kg.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.